ClinicalTrials.gg
RecruitingNCT07039916Updated Nov 13, 2026

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

A Phase 3 interventional study of IMVT-1402 and IMVT-1402 in Generalized Myasthenia Gravis, sponsored by Immunovant Sciences GmbH. Recruiting at 93 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Immunovant Sciences GmbH · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 13, 2026Site recruiting status changed5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
6th of 108
231 · median 56
Started
2025
with 12 others
Phase 3
45 of 144
9 open now
Primary completion
2027-12
later than 38 of 72 live
Registered
124th of 144
by date
Lead sponsor
3 of 144
Immunovant Sciences GmbH

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 6th largest by planned enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2025, is one of 45 in phase 3, reaches primary completion later than 38 of the 72 other live ones, and was the 124th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

03

Conditions studied

  • Generalized Myasthenia Gravis

Keywords

  • IMVT-1402
  • Generalized Myasthenia Gravis
  • Acetylcholine receptor
  • Muscle-specific kinase
  • Autoantibody
  • Lipoprotein receptor-related protein 4
  • Autoimmune disease
  • Neonatal fragment crystallizable receptor (FcRn)
  • Imeroprubart
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with the ability to understand the requirements of the trial, provide written , and comply with the trial protocol procedures.
  • Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit
  • Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1)

Additional inclusion criteria are defined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit.
  • Have had a thymectomy performed \< 6 months prior to the Screening Visit or have a planned thymectomy during the study
  • Have any active or untreated malignant thymoma

Additional exclusion criteria are defined in the protocol.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
231 participants (estimated)

Study arms

  • Experimental
    Group 1: IMVT-1402 Dose 1

    Drug: IMVT-1402

  • Experimental
    Group 2: IMVT-1402 Dose 2

    Drug: IMVT-1402

  • Placebo comparator
    Placebo/ IMVT-1402

    Drug: Placebo · Drug: IMVT-1402

Interventions

  • • Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)

  • * Dose 2 SC QW for 12 weeks (Period 1) * Dose 2 SC QW for 14 weeks (Period 2) * Dose 2 SC QW for 52 weeks (Period 3)

  • DrugPlacebo

    • Placebo SC QW for 12 weeks (Period 1)

  • * Dose 1 SC QW for 14 weeks (Period 2) * Dose 1 SC QW for 52 weeks (Period 3)

06

What researchers measure

Primary outcomes

  1. Change from Baseline in MG-ADL Score for Antibody-positive Participants

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change from Baseline in Quantitative Myasthenia Gravis (QMG) Score for Antibody-positive Participants

    Time frame: Baseline to Week 12

  2. Percentage of Antibody-positive Participants Achieving MG-ADL Score of 0 or 1

    Time frame: Week 12

  3. Percentage of Antibody-positive Participants with ≥50% Improvement in MG-ADL Score

    Time frame: Baseline to Week 12

07

Study locations

87 of 93 sites recruiting
  • Site Number - 1056
    Huntsville, Alabama 35801, United States
    Recruiting
  • Site Number - 1041
    Mobile, Alabama 36604, United States
    Recruiting
  • Site Number - 1017
    Phoenix, Arizona 85028, United States
    Recruiting
  • Site Number - 1025
    Scottsdale, Arizona 85251, United States
    Recruiting
  • Site Number - 1042
    Tucson, Arizona 85718, United States
    Recruiting
  • Site Number - 1010
    Carlsbad, California 92011, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Site Number - 1028
    Irvine, California 92697, United States
    Recruiting
  • Site Number - 1023
    Los Angeles, California 90033, United States
    Recruiting
  • Site Number - 1029
    Rancho Mirage, California 92270, United States
    Recruiting
  • Site Number - 1004
    San Francisco, California 94143, United States
    Recruiting
  • Site Number - 1053
    Denver, Colorado 80206, United States
    Recruiting
  • Site Number - 1027
    Fort Collins, Colorado 80528, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Site Number - 1001
    New Haven, Connecticut 06510, United States
    Recruiting
  • Site Number - 1024
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Site Number - 1006
    Clearwater, Florida 33761, United States
    Recruiting
  • Site Number - 1008
    Miami, Florida 33136, United States
    Recruiting
  • Site Number - 1037
    Ormond Beach, Florida 32174, United States
    Recruiting
  • Site Number - 1002
    Port Charlotte, Florida 33952, United States
    Recruiting
  • Site Number - 1050
    Rockledge, Florida 32955, United States
    Recruiting
  • Site Number - 1007
    Tampa, Florida 33612, United States
    Recruiting
  • Site Number - 1014
    Atlanta, Georgia 30329, United States
    Recruiting
  • Site Number - 1043
    Augusta, Georgia 30912, United States
    Recruiting
  • Site Number - 1054
    Schaumburg, Illinois 60173, United States
    Recruiting
  • Site Number - 1022
    Lexington, Kentucky 40536-0284, United States
    Recruiting
  • Site Number - 1032
    Nicholasville, Kentucky 40356, United States
    Recruiting
  • Site Number - 1046
    New Orleans, Louisiana 70121, United States
    Recruiting
  • Site Number - 1049
    Foxborough, Massachusetts 02035, United States
    Recruiting
  • Site Number - 1026
    Detroit, Michigan 48201, United States
    Recruiting
  • Site Number - 1005
    East Lansing, Michigan 48824, United States
    Recruiting
  • Site Number - 1018
    Omaha, Nebraska 68198, United States
    Recruiting
  • Site Number - 1019
    Totowa, New Jersey 07512, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Site Number - 1036
    New York, New York 10021, United States
    Recruiting
  • Site Number - 1034
    New York, New York 10065, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Site Number - 1020
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • Site Number - 1013
    Durham, North Carolina 27710, United States
    Recruiting
  • Site Number - 1044
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Site Number - 1038
    Cincinnati, Ohio 45221, United States
    Recruiting
  • Site Number - 1045
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Site Number - 1011
    Yukon, Oklahoma 73099, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Site Number - 1031
    Eugene, Oregon 97477, United States
    Recruiting
  • Site Number - 1030
    Charleston, South Carolina 29425, United States
    Recruiting
  • Site Number - 1015
    Charleston, South Carolina 29486, United States
    Recruiting
  • Site Number - 1021
    Memphis, Tennessee 38120, United States
    Recruiting
  • Site Number - 1003
    Dallas, Texas 75206, United States
    Recruiting
  • Site Number - 1047
    Denton, Texas 76208, United States
    Recruiting
  • Site Number - 1057
    Houston, Texas 77054, United States
    Recruiting
  • Site Number - 1048
    Lubbock, Texas 79414, United States
    Recruiting
  • Site Number - 1009
    Charlottesville, Virginia 22903, United States
    Recruiting
  • Site Number - 1040
    Richmond, Virginia 23298, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Site Number - 1035
    Greenfield, Wisconsin 53228, United States
    Recruiting
  • Site Number - 5003
    Caba, C1428AQK, Argentina
    Recruiting
  • Site Number - 5002
    Rosario, S2000, Argentina
    Recruiting
  • Site Number - 3201
    Brno, 60300, Czechia
    Recruiting
  • Site Number - 3601
    Copenhagen, 2177, Denmark
    Recruiting
  • Site Number - 8002
    Tbilisi, 0114, Georgia
    Recruiting
  • Site Number - 8003
    Tbilisi, 114, Georgia
    Recruiting
  • Site Number - 8001
    Tbilisi, 159, Georgia
    Recruiting
  • Site Number - 6502
    Bochum, 44791, Germany
    Recruiting
  • Site Number - 6504
    Goettigen, 37075, Germany
    Recruiting
  • Site Number - 6505
    Magdeburg, 39120, Germany
    Recruiting
  • Site Number - 6503
    Würzburg, 97070, Germany
    Recruiting
  • Site Number - 3903
    Athens, 11528, Greece
    Recruiting
  • Site Number - 3902
    Athens, 12462, Greece
    Recruiting
  • Site Number - 3901
    Pátrai, 26504, Greece
    Recruiting
  • Site Number - 3904
    Thessaloniki, 54642, Greece
    Recruiting
  • Site Number - 7552
    Budapest, 1085, Hungary
    Recruiting
  • Site Number - 7553
    Budapest, 1204, Hungary
    Recruiting
  • Site Number - 7551
    Kistarcsa, 2143, Hungary
    Recruiting
  • Site Number - 6003
    Bergamo, 24127, Italy
    Recruiting
  • Site Number - 6002
    Milan, 20133, Italy
    Recruiting
  • Site Number - 6001
    Naples, 80131, Italy
    Recruiting
  • Site Number - 6006
    Pisa, 56126, Italy
    Recruiting
  • Site Number - 6004
    Rome, 136, Italy
    Recruiting
  • Site Number - 2601
    Mexico City, 6700, Mexico
    Recruiting
  • Site Number - 2602
    Mexico City, 6700, Mexico
    Recruiting
  • Site Number - 3005
    Gdansk, 80-214, Poland
    Recruiting
  • Site Number - 3001
    Katowice, 40-689, Poland
    Recruiting
  • Site Number - 3006
    Krakow, 31-324, Poland
    Recruiting
  • Site Number - 3002
    Krakow, 31-503, Poland
    Recruiting
  • Site Number - 3003
    Krakow, 31-505, Poland
    Recruiting
  • Site Number - 3004
    Lublin, 20-701, Poland
    Recruiting
  • Site Number - 3007
    Warsaw, 01-684, Poland
    Recruiting
  • Site Number - 7503
    Brasov, 500283, Romania
    Recruiting
  • Site Number - 7502
    Constanța, 900348, Romania
    Recruiting
  • Site Number - 7501
    Târgu Mureş, 540136, Romania
    Recruiting
  • Site Number - 9001
    Belgrade, 11000, Serbia
    Recruiting
  • Site Number - 9002
    Niš, 18000, Serbia
    Recruiting
  • Site Number - 7103
    Barcelona, 8195, Spain
    Recruiting
  • Site Number - 7101
    Córdoba, 14011, Spain
    Recruiting
  • Site Number - 7104
    Madrid, 28034, Spain
    Recruiting
  • Site Number - 7003
    Birmingham, B15 2GW, United Kingdom
    Recruiting
  • Site Number - 7002
    Glasgow, G51 4TF, United Kingdom
    Recruiting
  • Site Number - 7004
    London, WC1N 3BG, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 31 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
May 27, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added. 6 sites changed recruiting status (6 now withdrawn)
Show 6 sites
  • Site Number - 1010 · Carlsbad, United StatesRecruiting→Withdrawn
  • Site Number - 1027 · Fort Collins, United StatesRecruiting→Withdrawn
  • Site Number - 1019 · Totowa, United StatesRecruiting→Withdrawn
  • Site Number - 1034 · New York, United StatesRecruiting→Withdrawn
  • Site Number - 1011 · Yukon, United StatesRecruiting→Withdrawn
  • Site Number - 1040 · Richmond, United StatesRecruiting→Withdrawn
Show 5 added (2 United States, 1 Italy, 1 Mexico, 1 Romania)
  • Site Number - 1053 · Denver, United States
  • Site Number - 1008 · Miami, United States
  • Site Number - 6006 · Pisa, Italy
  • Site Number - 2601 · Mexico City, Mexico
  • Site Number - 7503 · Brasov, Romania
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    5 sites added. 6 sites changed recruiting status (6 now withdrawn)
    Show 6 sites
    • Site Number - 1010 · Carlsbad, United StatesRecruiting→Withdrawn
    • Site Number - 1027 · Fort Collins, United StatesRecruiting→Withdrawn
    • Site Number - 1019 · Totowa, United StatesRecruiting→Withdrawn
    • Site Number - 1034 · New York, United StatesRecruiting→Withdrawn
    • Site Number - 1011 · Yukon, United StatesRecruiting→Withdrawn
    • Site Number - 1040 · Richmond, United StatesRecruiting→Withdrawn
    Show 5 added (2 United States, 1 Italy, 1 Mexico, 1 Romania)
    • Site Number - 1053 · Denver, United States
    • Site Number - 1008 · Miami, United States
    • Site Number - 6006 · Pisa, Italy
    • Site Number - 2601 · Mexico City, Mexico
    • Site Number - 7503 · Brasov, Romania
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07039916
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
Jun 26, 2025
Start date
May 27, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Central Study Contact
Contact
clinicaltrials@immunovant.com
18007970414

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeroprubart

Start the discussion